Iranian Scientists Unveil 4 Vital Cancer, Diabetes Drugs

Tuesday, May 7, 2019 - 10:55

Iranian scientists have unveiled two vital cancer drugs and two medicines commonly taken by diabetic patients.

According to an ISCA report, the two cancer drugs, unveiled in Tehran on Tuesday in the presence of Iranian Vice-President for Science and Technology Sorena Sattari and Health Minister Saeed Namaki, are named Regorafenib and Sorafenib.

Regorafenib is an oral multi-kinase inhibitor which targets angiogenic, stromal and oncogenic receptor tyrosine kinase and will be sold in Iran less than 5% of the price of its imported rival products. The drug shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition.

Also, Sorafenib is a kinase inhibitor drug licensed for the treatment of primary kidney cancer, advanced primary liver cancer, FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.

Meantime, the two commonly-used Empagliflozin and Dapagliflozin drugs, used for diabetes treatment, have been produced by Iranian scientists. Iran has taken long strides in producing different types of drugs and medical equipment.


Popular News

Latest News